Teleflex Incorporated · NYSE:TFX
Teleflex — Raymond James Institutional Investors Conference 2024
20 slides from Teleflex's conference presentation, Mar 5, 2024
Slide 1: Raymond James Institutional Investors Conference
Raymond James Institutional Investors Conference March 5, 2024 1
Slide 2: Forward Looking Statements – Investor Presentation
Forward Looking Statements – Investor Presentation This presentation and our discussion contain The forward-looking statements included in this forward-looking information and statements, which presentation should not be unduly relied upon. inherently involve risks and uncertainties that could These
Slide 3: We are a Strong Company
We are a Strong Company 23,000+ 14,500+ $3.0 80,000+ Industry products Employees Billion in customers leading globally revenue brands *Number of products calculated based on the number of stock keeping units offered by the company. Note: Product and customer data presented is as of December 31, 2022
Slide 4: We Add Value Across Key Clinical Areas
We Add Value Across Key Clinical Areas Specialty and Complex Comprehensive Vascular Access Catheters, Large Bore Femoral Arterial Access Site Closure Clip Ligation, Surgical Instruments and Internal Surgical Stapling Emergency Medicine MIS treatment for BPH, Rectal Spacing 4
Slide 5: Teleflex Has Delivered for Shareholders
Teleflex Has Delivered for Shareholders Solid Constant Currency Transformative Adjusted Robust Shareholder Return Revenue Growth From Margin Expansion From 2011-20232 2011-20231 1,190bp Adjusted 59.5% 6.1% Gross Margin 47.6% ~433% 750bp Adjusted Operating 26.5% 19.0% Margin 2011 2023 Portfolio optim
Slide 6: Teleflex Strategy 2023-2025
Teleflex Strategy 2023-2025 Deliver Long-Term Durable Growth 1. 2. 3. 4. Drive Achieve margin Optimize our Advance sustainable and earnings product corporate social revenue expansion portfolio responsibility growth and an inclusive culture 6
Slide 7: Drive Sustainable Revenue Growth
Drive Sustainable Revenue Growth Balanced Portfolio with Multiple Market-Leading, High Growth Franchises Interventional Urology Products Hemostatic Products Intraosseous Access High Growth PICC Portfolio Portfolio 1 Titan SGS Stapler® 25% High Growth Portfolio Other 2 MANTA® Vascular Closure Device
Slide 8: New Product Highlights - 2023
New Product Highlights - 2023 Vascular Access Surgical • Launched the VPS Rhythm® DLX Device with • Launched the Standard Bougie® to be used with the Titan TipTackerTM Technology and the NaviCurveTM Stylet, Stapler which enable more efficient and predictable PICC • Selected W.L. Gore & Associates Go
Slide 9: Achieve Earnings and Margin Expansion
Achieve Earnings and Margin Expansion Portfolio Restructuring Distributor to Mix Activities Direct Conversions High Growth portfolio will Expect to deliver Execute on our acquisition continue to drive margin $24-$26M in pre-tax strategy, and reload on our expansion over time. savings for opportuniti
Slide 10: Optimize Our Product Portfolio
Optimize Our Product Portfolio 80+ deals closed1 $5.4B1 New Product Strategic M&A transaction Introductions and Divestitures value Note: 1. From January 2011 to December 2023. 11
Slide 11: Strong Track Record of Disciplined M&A Execution
Strong Track Record of Disciplined M&A Execution Select Transactions Vidacare 2013 Strategic Asset Financial Asset Criteria Criteria • Category leadership • Accretive to revenue • Obvious clinical benefits growth • Ability to lower the • Accretive to margins overall cost of care • Exceeds our WACC i
Slide 12: Advance Corporate Social Responsibility and an Inclusive Culture
Advance Corporate Social Responsibility and an Inclusive Culture Community & Sustainable Ethics & Governance Planet & Environment People Healthcare • Corporate Governance • GHG Emission Reduction • Talent Management • Philanthropy • Public Policy • Sustainable Procurement • Employee Engagement & • C
Slide 13: Disciplined Capital Allocation Framework
Disciplined Capital Allocation Framework 15
Slide 14: Thank You
Teleflex Investor Presentation Thank You 16
Slide 15: Appendix
Appendix GAAP to Non-GAAP Reconciliations 17
Slide 16: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures The presentation to which these appendices are attached, and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: • Constant currency revenue gr
Slide 17: Non-GAAP Adjustments
Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non- Legal entity rationalization items. These adjustments represent direct and incremental costs and discrete changes GAAP financial measures that appear in the pre
Slide 18: Appendix A – Reconciliation of Constant Currency Revenue Growth, 2011-2023
Appendix A – Reconciliation of Constant Currency Revenue Growth, 2011-2023 Dollars in Millions Twelve Months Ended Revenue Year-Over-Year Percent Change 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Prior Year Ended
Slide 19: Appendix B – Reconciliation of Adjusted Gross Profit and Margin
Appendix B – Reconciliation of Adjusted Gross Profit and Margin Dollars in Thousands Twelve Months Ended Margin Expansion 12/31/11 12/31/23 2011-2023 Gross profit as-reported $ 708,778 $ 1,646,931 Gross margin as-reported 47.5% 55.4% Restructuring, restructuring related and impairment items - 23,269
Slide 20: Appendix C – Reconciliation of Adjusted Operating Profit and Margin
Appendix C – Reconciliation of Adjusted Operating Profit and Margin Dollars in Thousands Twelve Months Ended Margin Expansion 12/31/11 12/31/23 2011-2023 Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 229,570 $ 506,313 Income from continuing operations
Teleflex — Raymond James Institutional Investors Conference 2024 on 6ix